4//SEC Filing
Sanna Bastiano 4
Accession 0001209191-23-027374
CIK 0000875320other
Filed
May 3, 8:00 PM ET
Accepted
May 4, 4:51 PM ET
Size
12.4 KB
Accession
0001209191-23-027374
Insider Transaction Report
Form 4
Sanna Bastiano
EVP, Cell & Genetic Therapies
Transactions
- Sale
Common Stock
2023-05-02$350.32/sh−1,411$494,302→ 38,302 total - Sale
Common Stock
2023-05-02$351.65/sh−42$14,769→ 38,260 total - Sale
Common Stock
2023-05-02$353.24/sh−169$59,698→ 38,091 total - Sale
Common Stock
2023-05-03$350.44/sh−2,053$719,453→ 36,038 total - Sale
Common Stock
2023-05-03$351.60/sh−728$255,965→ 35,310 total
Footnotes (7)
- [F1]Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
- [F2]Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $350.32 (range $350.00 to $350.92).
- [F4]Open market sales reported on this line occurred at a weighted average price of $351.65 (range $351.48 to $351.80).
- [F5]Open market sales reported on this line occurred at a weighted average price of $353.24 (range $353.21 to $353.49).
- [F6]Open market sales reported on this line occurred at a weighted average price of $350.44 (range $350.00 to $350.94).
- [F7]Open market sales reported on this line occurred at a weighted average price of $351.60 (range $351.01 to $352.00).
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001829069
Filing Metadata
- Form type
- 4
- Filed
- May 3, 8:00 PM ET
- Accepted
- May 4, 4:51 PM ET
- Size
- 12.4 KB